• Harvard Bioscience Inc HBIO.OQ HBIO.O is expected to show a fall in quarterly revenue when it reports results on March 12 for the period ending December 31 2024

• The Holliston Massachusetts-based company is expected to report a 14.2% decrease in revenue to $24.15 million from $28.15 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.The company's guidance on November 7 2024, for the period ended December 31, was for revenue between $23.00 million and $26.00 million.

• ​LSEG's mean analyst estimate for Harvard Bioscience Inc is for earnings of 5 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Harvard Bioscience Inc is $6.25​, above​ its last closing price of $0.82. ​​​

The company's guidance on November 7 2024 for the period ended December 31 was for Earnings before Interest, Taxes, Depreciation and Amortization of between USD23 million and USD4.16 million.The company's guidance on November 7 2024 for the period ended December 31 was for gross profit margin between USD59% and USD60%.

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated March 10 at 12:56 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)